NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- State
- Under way
- Phase
- Phase 2
- People
- 890 planned
- Started
- 26 Feb 2024
- Primary completion
- 19 Nov 2030
- Arms
- HER3-DXd Monotherapy
- Results
- None posted
- 15 Dec 2023: Trial registered
- 26 Feb 2024: Trial started